Prof Stellah Mpagama

Open access

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
Heinrich, N., de Jager, V., Dreisbach, J., Gross-Demel, P., Schultz, S., Gerbach, S., Kloss, F., Dawson, R., Narunsky, K., Matt, L., Wildner, L., McHugh, T. D., Fuhr, U., Aldana, B. H., Mouhdad, C., Brake, L. T., Boeree, M. J., Aarnoutse, R. E., Svensson, E. M. & Gong, X. & 31 others, P J Phillips, P., Diacon, A. H., Hoelscher, M., Gross – Demel, P., Wagnerberger, L., Razid, A., Lutchmun, W., Noren᷉a, I., Paramo Diaz, L., Sabiiti, W., Sloan, D., Gillespie, S., te Brake, L., Svensson, E., Aarnoutse, R., Boeree, M., Stemkens, R., Koele, S., Bateson, A., Hunt, R., McHugh, T. D., Muraro Wildner, L., Solanki, P., Phillips, P., Aldana, B., Crook, A., Arnolds, S., Diacon, A., Mtafya, B., Mpagama, S. & PanACEA Consortium, 7 Jan 2025, (E-pub ahead of print) In: The Lancet Microbe. In Press, 12 p., 100952.
Research output: Contribution to journal › Article › peer-review

People